Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troxatyl in AML Second Salvage
NCT00129948Phase 2Terminated
- Sponsor
- SGX Pharmaceuticals, Inc.
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of troxerutin in acute myeloid leukemia (AML), sponsored by SGX Pharmaceuticals, Inc. Primary endpoint: Complete Response Rate. Started Jul 2005; status: terminated.
02
Drugs
troxerutin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00129948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129948.